00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
surmount-4 tirzepatide withdrawal weight regain for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Trajectory of weight regain after
Description
In a pool of placebo-controlled trials, gastrointestinal adverse effects occurred in more than 5% of patients taking tirzepatide
Type 2 diabetes was identified in 3.4% of the group
Eating small meals, avoiding fatty foods, and consuming plenty of fiber can help
Tirzepatide is injected subcutaneously into fatty tissue, not ingested orally, so whether your stomach is full or empty does not affect absorption or efficacy
Common mistakes with Olympia tirzepatide dosing Years of patient experiences and provider feedback have revealed consistent patterns of dosing errors
